SGD Pharma Launches Sterile Nasal Vial Platform for US Market

On March 17, 2026, SGD Pharma announced a strategic original equipment manufacturer collaboration with Prince Sterilization Services, LLC to validate ready-to-use type I glass primary packaging solutions for the North American market.¹ The first commercial outcome of that collaboration is the My Sterinity Nasal platform, a flexible cleaned vial range built on SGD Pharma's existing My Sterinity platform that will be formally introduced at DCAT Week 2026 in New York.

The announcement signals the availability of a regionally qualified, end-to-end supply chain for sterile Type I glass nasal vials, an offering that has historically been difficult to source with short lead times in the US.¹

Why Is the Nasal Delivery Market Drawing Renewed Attention to Glass Packaging?

The global nasal drug delivery market is valued at approximately €9 billion ($10.4 billion) and encompasses more than 2 billion units annually.¹ Plastic has historically dominated this segment, accounting for roughly 88% of packaging formats. However, the therapeutic profile of nasal drug programs is shifting. What was once a market concentrated on acute and rescue treatments is now expanding into chronic, high-value indications for conditions that include Alzheimer's disease, Parkinson's disease, multiple sclerosis and depression.

These longer-duration therapies place more demanding requirements on primary packaging.¹ Formulation teams need containers that offer strong chemical inertness, consistent barrier protection and long-term biocompatibility. Minimizing adsorption of active compounds, preserving sterility over extended treatment courses and enabling precision dosing are increasingly non-negotiable for this category. Type I borosilicate glass satisfies these criteria in ways that plastic alternatives often cannot.

What Will the SGD Pharma and Prince Collaboration Deliver?

My Sterinity Nasal launches initially in three vial formats--0.5 mL, 7.5 mL and 10 mL--that are available in both clear and amber glass.¹ The vials are based on SGD Pharma's U-Save type I glass and offer controlled particulate and endotoxin levels, validated sterility assurance and compatibility with standard preservative-free nasal pump systems. They are packaged in double-bagged trays for immediate deployment in filling operations.

The division of responsibilities in the collaboration is designed to address a practical gap in the North American supply landscape.¹ Glass manufacturing will take place at SGD Pharma's Saint Quentin La-Motte facility in northern France, which holds ISO 15378 certification and operates to GMP standards. Prince will then handle washing, depyrogenation and sterilization services on the North American side, creating a qualified, regional supply chain suited to US biopharmaceutical customers.

Carole Grassi, chief commercial marketing & innovation officer, SGD Pharma, said in a press release,¹ “Our collaboration with Prince marks an important milestone in SGD Pharma's innovation growth strategy for North America. The My Sterinity Nasal platform represents a major step forward in high-value nasal drug delivery, and our collaboration with Prince unlocks immediate US-qualified capacity for biopharma customers scaling complex nasal therapy programs. This is more than a product launch, it is a validated supply chain ready to support qualification, clinical trials and commercial launch with unmatched speed and reliability.”

Daniel Prince, PhD, CEO, Prince Sterilization Services, said, in the press release,¹ "SGD Pharma's Type I glass expertise combined with our quality focused and flexible RTU & sterilization platform creates the gold standard for sterile nasal packaging. Prince's recent US qualification means we can now deliver ready-to-use, terminally sterilized My Sterinity Nasal vials in timelines that match domestic and international customer development cycles and exceed quality requirements."

The practical implication is access to terminally sterilized, type I molded glass vials without the delays typically associated with custom qualification projects or international shipping timelines.¹ SGD Pharma's broader type I molded glass portfolio is characterized by high hydrolytic resistance, low thermal expansion. This being relevant for lyophilization and autoclaving processes.

What Else Is Being Presented at DCAT Week 2026?

Alongside the My Sterinity Nasal launch, SGD Pharma will present two additional glass packaging technologies at DCAT Week.¹ Sealian is an internal surface treatment designed to improve chemical durability and barrier performance for sensitive drug formulations. The company will also present Idency premium vials, which are engineered to provide greater chemical and mechanical resistance than standard tubular vials while retaining the same outer diameter. Idency allows integration with existing filling line configurations without equipment modification.

SGD Pharma will not be alone in addressing supply chain resilience in injectable and specialty drug segments.² Avenacy, a US-based specialty pharmaceutical company, will discuss its portfolio of twenty-six critical acute care and shortage injectable medications. The company is using the conference to engage potential customers and partners around further product launches aimed at stabilising supply in high-demand categories.

Lotte Biologics will also be present at DCAT Week 2026, using the event to advance CDMO partnership discussions in the North American market and beyond.³ The company plans to highlight the combined capabilities of its Syracuse bio campus in New York and Plant 1 at its Songdo facility in Incheon, South Korea. Lotte will present a cell line development to drug substance production timeline of approximately 8.5 months, achieved through a partnership with Asimov. Manufacturing support spans monoclonal antibodies, bispecific antibodies and both clinical and commercial-scale production. The presences of these organizations at DCAT Week 2026 reflects a broader industry preoccupation with qualified, reliable supply chains for complex drug delivery formats.

References

1. SGD Pharma. SGD Pharma advances its North American pharmaceutical glass offering in new collaboration with Prince Sterilization Services, LLC – debuting its My Sterinity Nasal range at DCAT Week 2026. Paris La Défense, France: SGD Pharma; March 17, 2026. Press release.
2. ​Avenacy. Avenacy to attend 2026 DCAT Week. Business Wire. March 16, 2026. Accessed March 18, 2026. https://www.businesswire.com/news/home/20260316315025/en/Avenacy-to-Attend-2026-DCAT-Week
3. Korea Biomedical Review. Lotte Biologics to participate in DCAT Week 2026 in New York. Korea Biomedical Review. March 17, 2026. Accessed March 18, 2026. https://www.koreabiomed.com/news/articleView.html?idxno=30848